Analysis of Revenues
Revenues as Reported
Cytokinetics Inc., income statement, revenues
US$ in thousands
| 12 months ended: | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 94,588) | 70,428) | 55,828) | 26,868) | 31,501) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Revenue exhibits a notable upward trajectory over the analyzed five-year period, characterized by an initial slight decline followed by a period of accelerated and sustained growth. Between 2018 and 2022, total revenues increased from US$ 31,501 thousand to US$ 94,588 thousand, representing a substantial overall expansion of the top line.
- Initial Revenue Contraction
- A downward trend is observed between 2018 and 2019, with revenues decreasing from US$ 31,501 thousand to US$ 26,868 thousand, reflecting a decline of approximately 14.7%.
- Growth Inflection Point
- A significant reversal occurred in 2020, where revenues experienced a sharp increase to US$ 55,828 thousand. This represents a year-over-year growth rate of approximately 107.8%, signaling a primary shift in the company's revenue generation capacity.
- Sustained Upward Momentum
- The growth trend persisted through the final two years of the period. Revenues rose by approximately 26.1% in 2021 to reach US$ 70,428 thousand, and further expanded by 34.3% in 2022 to conclude at US$ 94,588 thousand.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?